Published in Bioorg Med Chem on December 01, 1999
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem (2009) 1.10
Substituted imidazo[1,2-a]pyridines as β-strand peptidomimetics. Org Lett (2012) 0.79
Synthesis and conformational analysis of bicyclic extended dipeptide surrogates. J Org Chem (2010) 0.78
Isoprenoid biosynthesis in Plasmodium falciparum. Eukaryot Cell (2014) 0.77
Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. J Med Chem (2010) 0.77
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
The location of paravertebral catheters placed using the landmark technique. Anaesthesia (2012) 2.13
Quantitative studies of in situ immune complex glomerulonephritis in the rat induced by planted, cationized antigen. J Exp Med (1982) 2.00
The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. J Biol Chem (1997) 1.98
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene (2000) 1.80
Solid-phase enzyme immunoassay for immunoglobulin M antibodies to cytomegalovirus. J Clin Microbiol (1977) 1.75
Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem (1995) 1.75
Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an alpha-helix. J Am Chem Soc (2001) 1.67
Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol (1989) 1.66
Peptide and protein recognition by designed molecules. Chem Rev (2000) 1.61
Complement and monocytes are essential for provoking glomerular injury in passive Heymann nephritis in rats. Terminal complement components are not the sole mediators of proteinuria. Lab Invest (1991) 1.55
Interaction of cationized antigen with rat glomerular basement membrane: in situ immune complex formation. Kidney Int (1982) 1.53
A model of in situ immune complex glomerulonephritis in the rat employing cationized ferritin. Clin Nephrol (1980) 1.51
Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) J Am Coll Cardiol (1992) 1.50
Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis. J Exp Med (1989) 1.48
Medical professional involvement in smartphone 'apps' in dermatology. Br J Dermatol (2012) 1.46
Cationic antigens in poststreptococcal glomerulonephritis. Clin Nephrol (1983) 1.39
The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol (2000) 1.39
The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem (1997) 1.35
Electron microscopic localization of the nephrotoxic antibody in the glomeruli of the rat after intravenous application of purified nephritogenic antibody-ferritin conjugates. J Exp Med (1968) 1.35
Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem (1995) 1.33
Incidence, management, and outcome of stent loss during intracoronary stenting. Am J Cardiol (2001) 1.31
False positive results for leucocytes in urine dipstick test with common antibiotics. BMJ (1996) 1.29
Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem (2000) 1.27
Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem (2001) 1.23
Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation (2000) 1.21
The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ (2010) 1.20
Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res (1995) 1.18
Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nat Biotechnol (2000) 1.18
p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA. Mol Cell Biol (1998) 1.18
Stimulation of DNA synthesis in cultures of mouse spleen cell suspensions by bovine transferrin. Exp Cell Res (1969) 1.18
A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene (2007) 1.17
Hair follicles--an efficient storage and penetration pathway for topically applied substances. Summary of recent results obtained at the Center of Experimental and Applied Cutaneous Physiology, Charité -Universitätsmedizin Berlin, Germany. Skin Pharmacol Physiol (2008) 1.12
The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res (1996) 1.11
Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression. Mol Biol Cell (2000) 1.11
GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res (1997) 1.11
RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem (2000) 1.10
Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. J Immunol (2000) 1.10
The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem (2001) 1.10
Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res (1998) 1.09
Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene (1996) 1.09
An active model of immune complex glomerulonephritis in the rat employing cationized antigen. Am J Pathol (1983) 1.08
Bleomycin: a pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis. Pharmacol Ther (1990) 1.08
Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem (1999) 1.08
Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem (1996) 1.07
Ultrasound-guided paravertebral puncture and placement of catheters in human cadavers: an imaging study. Br J Anaesth (2009) 1.07
Enzyme-linked immunosorbent assay using recombinant OspC and the internal 14-kDa flagellin fragment for serodiagnosis of early Lyme disease. J Clin Microbiol (1998) 1.06
'In situ' immune complex nephritis and basic proteins. Proc Eur Dial Transplant Assoc (1980) 1.05
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene (2006) 1.05
Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I. J Med Chem (1999) 1.04
Antibody to streptococcal zymogen in the serum of patients with acute glomerulonephritis: a multicentric study. Kidney Int (1998) 1.03
Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene (2000) 1.02
Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells. Hepatology (2000) 1.01
Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol (1998) 1.01
The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J Biol Chem (1999) 1.00
N-terminal amino acid sequence of the Borrelia burgdorferi flagellin. FEMS Microbiol Lett (1989) 1.00
Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorg Med Chem Lett (2001) 0.99
Glomerular immune deposits in murine lupus models may contain histones. Clin Exp Immunol (1992) 0.98
Protein surface recognition by synthetic receptors based on a tetraphenylporphyrin scaffold. Org Lett (2000) 0.98
Masking of protein antigen by modification of amino groups with carbobenzoxychloride (benzyl chloroformate) and demasking by treatment with nonspecific protease. J Histochem Cytochem (1978) 0.98
Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. J Biol Chem (1993) 0.97
Synthesis of complement components (C3, C2, B and C1-inhibitor) and lysozyme by human monocytes and macrophages. J Clin Lab Immunol (1986) 0.97
Immuno-electron microscopic localization of lipopolysaccharide antigens on ultrathin sections of Salmonella typhimurium. J Bacteriol (1979) 0.96
Hemodynamic effects of nisoldipine in chronic congestive heart failure. Arzneimittelforschung (1983) 0.96
Staphylococcal neutral phosphatase. A highly cationic molecule with binding properties for immunoglobulin. APMIS (1994) 0.96
Further studies on the immunoelectronmicroscopic localization of polysaccharide antigens on ultra-thin sections of Candida albicans. Mykosen (1985) 0.95
Glomerular injury induced by cationic 70-kD staphylococcal protein; specific immune response is not involved in early phase in rats. J Pathol (1998) 0.95